Asthma

Allergists discuss the differing opinions of allergies and optimizing patient care during the COVID-19 pandemic.

New data from the Liberty Asthma VOYAGE study saw fewer asthma exacerbations and improved lung function in this patient population.

Investigators detail the clinical criteria of the condition and speak to the safety of the COVID-19 vaccine for this patient population.

Investigators suggested that peer-led asthma program implemented in venues such as schools, houses of worship, or clinics can improve access to asthma education.

Authors suggest children with uncontrolled asthma should be considered for priority for COVID-19 vaccination.

Despite some overlapping risk factors, investigators noted that no common risk factors were identified in all 3 conditions.

Investigators added that this risk might possibly be through intrauterine effects, while associations with wheezing might be confounded by familial clustering factors.

Further research is needed to devise strategies for the prevention and treatment of asthma attacks.

Despite this, asthma severity was not associated with higher risk of COVID-19.

To date, dupilumab is the only medicine to show clinically meaningful phase 3 results in this patient population, with regulatory fillings planned for 2022.

The indication makes 6 to 11-year-old children with eosinophilic biomarkers or corticosteroid dependency eligible for the biologic add-on therapy.

New data reveals that the pandemic led to significantly less medicines being taken by pediatric patients during the first lockdown in Finland.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.

Dr. Owotomo and fellow investigators evaluated 1298 children from the Washington DC area and found that called for greater asthma care by pulmonologists and allergists alike.

Dr. Hernandez-Trujilo speaks of her personal history with food allergy, and what she recommends for families and expecting parents in the management of pediatric food allergy.

The long-term study from Denmark also found a strong association between gender and loss of asthma control, among other factors.

Investigators also reported an increase in individualized FeNO associated with young female patients.

Dr. Castro considers it to be a fruitful and exciting time in the study of asthma-modifying therapy, with some biologic therapies achieving control in patients with severe asthma.

Investigators believe these findings can help identify high-risk groups and prevent exacerbations through tailored treatments.

Dr. Castro talks of the available biologic therapies that can be used to treat asthma and other respiratory disorders.

Dr. Castro defines type 2 inflammation and the complications surrounding severe asthma, as well as several biomarkers including IgE levels, blood eosinophils, and exhaled nitric oxide.

Though previous studies have measured different levels of physical activity, few before this have considered the interrelationship involving body mass index and childhood asthma control.

As predicted, previous asthma during early childhood was a strong risk factor for asthma in young adulthood.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

In an interview with HCPLive, Dr. Jean-Pierre Llanos-Ackert and Dr. Bill Cook discuss how tezepelumab resulted in improved lung function and an 86% reduction in exacerbation rates in this patient population.

Despite cautionary programs and air purifiers having been installed in the school to alleviate allergic symptoms, investigators found they did not significantly reduce symptom-days.

Dr. Castro and Dr. Rizzo discuss the evolving world of monoclonal antibodies for severe asthma. Plus, the ALA team discusses September's annual Asthma Peak Week, and what it means for reopening schools.

As with previous studies, the investigators found that the biologic aided in reducing severe exacerbations and improving lung function in patients with evidence type 2 inflammation.

Despite conflicting data, investigators form Spain found that gastroesophageal reflux disease and asthma are bidirectional, with each disease exacerbating each other.

Investigators found that intralymphatic immunotherapy of was not superior to placebo or other forms of allergen-specific immunotherapy, but felt continued research was warranted.